39 results on '"Brugnano R"'
Search Results
2. IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?
- Author
-
Brugnano, R., Del Sordo, R., Covarelli, C., Gnappi, E., and Pasquali, S.
- Published
- 2016
- Full Text
- View/download PDF
3. Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies/immune complex–Mediated membranoproliferative GN
- Author
-
Iatropoulos, P, Daina, E, Curreri, M, Piras, R, Valoti, E, Mele, C, Bresin, E, Gamba, S, Alberti, M, Breno, M, Perna, A, Bettoni, S, Sabadini, E, Murer, L, Vivarelli, M, Noris, M, Remuzzi, G, Bottanelli, L, Donadelli, R, Cuccarolo, P, Abbate, M, Carrara, C, Cannata, A, Ferrari, S, Gaspari, F, Stucchi, N, Bassani, C, Lena, M, Omati, G, Taruscia, D, Bellantuono, R, Giordano, M, Messina, G, Caruso, M, Gotti, E, Mescia, F, Perticucci, E, Schieppati, A, Verdoni, L, Berto, M, Baraldi, O, Montini, G, Pasini, A, Passler, W, Degasperi, T, Gaggiotti, M, Gregorini, G, Miglietti, N, Guarnieri, A, Cirami, L, Roperto, R, Di Giorgio, G, Barbano, G, Innocenti, M, Ghiggeri, G, Magnasco, A, Rolla, D, Casartelli, D, Lambertini, D, Maggio, M, Cosci, P, Conti, G, Amar, K, Ardissino, G, Marinosci, A, Sinico, R, Montoli, A, Bonucchi, D, Facchini, F, Furci, L, Ferretti, A, Nuzzi, F, Pecoraro, C, Visciano, B, Canavese, C, Radin, E, Stratta, P, Nordio, M, Benetti, E, Parolin, M, Alberici, F, Manenti, L, Brugnano, R, Manenti, F, Capitanini, A, Emma, F, Massella, L, Rosa, M, Mazzon, M, Basso, E, Besso, L, Lavacca, A, Mella, A, Bertero, M, Coppo, R, Peruzzi, L, Porcellini, M, Piccoli, G, Clari, R, Pasi, A, Gangemi, C, Alfandary, H, Dagan, A, Conceiçao, M, Sameiro, F, Croze, L, Malvezzi, P, Tsygin, A, Zelan, B, Nastasi, N, Iatropoulos, Paraskevas, Daina, Erica, Curreri, Manuela, Piras, Rossella, Valoti, Elisabetta, Mele, Caterina, Bresin, Elena, Gamba, Sara, Alberti, Marta, Breno, Matteo, Perna, Annalisa, Bettoni, Serena, Sabadini, Ettore, Murer, Luisa, Vivarelli, Marina, Noris, Marina, Remuzzi, Giuseppe, Bottanelli, L., Donadelli, R., Cuccarolo, P., Abbate, M., Carrara, C., Cannata, A., Ferrari, S., Gaspari, F., Stucchi, N., Bassani, C., Lena, M., Omati, G., Taruscia, D., Bellantuono, R., Giordano, M., Messina, G., Caruso, M., Gotti, E., Mescia, F., Perticucci, E., Schieppati, A., Verdoni, L., Berto, M., Baraldi, O., Montini, G., Pasini, A., Passler, W., Degasperi, T., Gaggiotti, M., Gregorini, G., Miglietti, N., Guarnieri, A., Cirami, L., Roperto, R. M., Di Giorgio, G., Barbano, G., Innocenti, M. L. D., Ghiggeri, G. M., Magnasco, A., Rolla, D., Casartelli, D., Lambertini, D., Maggio, M., Cosci, P. M., Conti, G., Amar, K., Ardissino, G., Marinosci, A., Sinico, R. A., Montoli, A., Bonucchi, D., Facchini, F., Furci, L., Ferretti, A., Nuzzi, F., Pecoraro, C., Visciano, B., Canavese, C., Radin, E., Stratta, P., Nordio, M., Benetti, E., Parolin, M., Alberici, F., Manenti, L., Brugnano, R., Manenti, F., Capitanini, A., Emma, F., Massella, L., Rosa, M., Mazzon, M., Basso, E., Besso, L., Lavacca, A., Mella, A., Bertero, M., Coppo, R., Peruzzi, L., Porcellini, M. G., Piccoli, G. B., Clari, R., Pasi, A., Gangemi, C., Alfandary, H., Dagan, A., Conceiçao, M., Sameiro, F. M., Croze, L., Malvezzi, P., Tsygin, A., Zelan, B., Nastasi, null, Iatropoulos, P, Daina, E, Curreri, M, Piras, R, Valoti, E, Mele, C, Bresin, E, Gamba, S, Alberti, M, Breno, M, Perna, A, Bettoni, S, Sabadini, E, Murer, L, Vivarelli, M, Noris, M, Remuzzi, G, Bottanelli, L, Donadelli, R, Cuccarolo, P, Abbate, M, Carrara, C, Cannata, A, Ferrari, S, Gaspari, F, Stucchi, N, Bassani, C, Lena, M, Omati, G, Taruscia, D, Bellantuono, R, Giordano, M, Messina, G, Caruso, M, Gotti, E, Mescia, F, Perticucci, E, Schieppati, A, Verdoni, L, Berto, M, Baraldi, O, Montini, G, Pasini, A, Passler, W, Degasperi, T, Gaggiotti, M, Gregorini, G, Miglietti, N, Guarnieri, A, Cirami, L, Roperto, R, Di Giorgio, G, Barbano, G, Innocenti, M, Ghiggeri, G, Magnasco, A, Rolla, D, Casartelli, D, Lambertini, D, Maggio, M, Cosci, P, Conti, G, Amar, K, Ardissino, G, Marinosci, A, Sinico, R, Montoli, A, Bonucchi, D, Facchini, F, Furci, L, Ferretti, A, Nuzzi, F, Pecoraro, C, Visciano, B, Canavese, C, Radin, E, Stratta, P, Nordio, M, Benetti, E, Parolin, M, Alberici, F, Manenti, L, Brugnano, R, Manenti, F, Capitanini, A, Emma, F, Massella, L, Rosa, M, Mazzon, M, Basso, E, Besso, L, Lavacca, A, Mella, A, Bertero, M, Coppo, R, Peruzzi, L, Porcellini, M, Piccoli, G, Clari, R, Pasi, A, Gangemi, C, Alfandary, H, Dagan, A, Conceiçao, M, Sameiro, F, Croze, L, Malvezzi, P, Tsygin, A, Zelan, B, Nastasi, N, Iatropoulos, Paraskevas, Daina, Erica, Curreri, Manuela, Piras, Rossella, Valoti, Elisabetta, Mele, Caterina, Bresin, Elena, Gamba, Sara, Alberti, Marta, Breno, Matteo, Perna, Annalisa, Bettoni, Serena, Sabadini, Ettore, Murer, Luisa, Vivarelli, Marina, Noris, Marina, Remuzzi, Giuseppe, Bottanelli, L., Donadelli, R., Cuccarolo, P., Abbate, M., Carrara, C., Cannata, A., Ferrari, S., Gaspari, F., Stucchi, N., Bassani, C., Lena, M., Omati, G., Taruscia, D., Bellantuono, R., Giordano, M., Messina, G., Caruso, M., Gotti, E., Mescia, F., Perticucci, E., Schieppati, A., Verdoni, L., Berto, M., Baraldi, O., Montini, G., Pasini, A., Passler, W., Degasperi, T., Gaggiotti, M., Gregorini, G., Miglietti, N., Guarnieri, A., Cirami, L., Roperto, R. M., Di Giorgio, G., Barbano, G., Innocenti, M. L. D., Ghiggeri, G. M., Magnasco, A., Rolla, D., Casartelli, D., Lambertini, D., Maggio, M., Cosci, P. M., Conti, G., Amar, K., Ardissino, G., Marinosci, A., Sinico, R. A., Montoli, A., Bonucchi, D., Facchini, F., Furci, L., Ferretti, A., Nuzzi, F., Pecoraro, C., Visciano, B., Canavese, C., Radin, E., Stratta, P., Nordio, M., Benetti, E., Parolin, M., Alberici, F., Manenti, L., Brugnano, R., Manenti, F., Capitanini, A., Emma, F., Massella, L., Rosa, M., Mazzon, M., Basso, E., Besso, L., Lavacca, A., Mella, A., Bertero, M., Coppo, R., Peruzzi, L., Porcellini, M. G., Piccoli, G. B., Clari, R., Pasi, A., Gangemi, C., Alfandary, H., Dagan, A., Conceiçao, M., Sameiro, F. M., Croze, L., Malvezzi, P., Tsygin, A., Zelan, B., and Nastasi, null
- Abstract
Membranoproliferative GN (MPGN) was recently reclassified as alternative pathway complement–mediated C3 glomerulopathy (C3G) and immune complex–mediated membranoproliferative GN (IC-MPGN). However, genetic and acquired alternative pathway abnormalities are also observed in IC-MPGN. Here, we explored the presence of distinct disease entities characterized by specific pathophysiologic mechanisms. We performed unsupervised hierarchical clustering, a data-driven statistical approach, on histologic, genetic, and clinical data and data regarding serum/plasma complement parameters from 173 patients with C3G/IC-MPGN. This approach divided patients into four clusters, indicating the existence of four different pathogenetic patterns. Specifically, this analysis separated patients with fluid-phase complement activation (clusters 1–3) who had low serum C3 levels and a high prevalence of genetic and acquired alternative pathway abnormalities from patients with solid-phase complement activation (cluster 4) who had normal or mildly altered serum C3, late disease onset, and poor renal survival. In patients with fluid-phase complement activation, those in clusters 1 and 2 had massive activation of the alternative pathway, including activation of the terminal pathway, and the highest prevalence of subendothelial deposits, but those in cluster 2 had additional activation of the classic pathway and the highest prevalence of nephrotic syndrome at disease onset. Patients in cluster 3 had prevalent activation of C3 convertase and highly electron-dense intramembranous deposits. In addition, we provide a simple algorithm to assign patients with C3G/IC-MPGN to specific clusters. These distinct clusters may facilitate clarification of disease etiology, improve risk assessment for ESRD, and pave the way for personalized treatment.
- Published
- 2018
4. Renal Involvement in Systemic Amyloidosis: Report of an Italian Retrospective Study
- Author
-
Bergesio, F., primary, Ciciani, A.M., additional, Palladini, G., additional, Brugnano, R., additional, Bizzarri, D., additional, Pasquali, S., additional, and Salvadori, M., additional
- Published
- 2004
- Full Text
- View/download PDF
5. Renal Involvement in Systemic Amyloidosis
- Author
-
Ciciani, A, primary, Palladini, G, additional, Salvadori, M, additional, Brugnano, R, additional, Pasquali, S, additional, Bizzarri, D, additional, and Bergesio, F, additional
- Published
- 2004
- Full Text
- View/download PDF
6. Renal involvement in systemic amyloidosis*: An Italian collaborative study on survival and renal outcome
- Author
-
Bergesio, F., Ciciani, A. M., Manganaro, M., Palladini, G., Santostefano, M., Brugnano, R., Di Palma, A. M., Gallo, M., Rosati, A., Tosi, P. L., and Salvadori, M.
- Published
- 2008
7. Renal funtional reserve in kidney transplant recipients
- Author
-
Fagugli, R. M., Selvi, A., Brugnano, R., Cozzari, M., Buoncristiani, U., Fedeli, L., Kootstra, Gauke, editor, Opelz, Gerhard, editor, Buurman, W. A., editor, van Hooff, J. P., editor, MacMaster, P., editor, and Wallwork, J., editor
- Published
- 1992
- Full Text
- View/download PDF
8. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex–Mediated Membranoproliferative GN
- Author
-
Iatropoulos, Paraskevas, Daina, Erica, Curreri, Manuela, Piras, Rossella, Valoti, Elisabetta, Mele, Caterina, Bresin, Elena, Gamba, Sara, Alberti, Marta, Breno, Matteo, Perna, Annalisa, Bettoni, Serena, Sabadini, Ettore, Murer, Luisa, Vivarelli, Marina, Noris, Marina, Remuzzi, Giuseppe, Bottanelli, L., Donadelli, R., Cuccarolo, P., Abbate, M., Carrara, C., Cannata, A., Ferrari, S., Gaspari, F., Stucchi, N., Bassani, C., Lena, M., Omati, G., Taruscia, D., Bellantuono, R., Giordano, M., Messina, G., Caruso, M., Gotti, E., Mescia, F., Perticucci, E., Schieppati, A., Verdoni, L., Berto, M., Baraldi, O., Montini, G., Pasini, A., Passler, W., Degasperi, T., Gaggiotti, M., Gregorini, G., Miglietti, N., Guarnieri, A., Cirami, L., Roperto, R. M., Di Giorgio, G., Barbano, G., Innocenti, M. L. D., Ghiggeri, G. M., Magnasco, A., Rolla, D., Casartelli, D., Lambertini, D., Maggio, M., Cosci, P. M., Conti, G., Amar, K., Ardissino, G., Marinosci, A., Sinico, R. A., Montoli, A., Bonucchi, D., Facchini, F., Furci, L., Ferretti, A., Nuzzi, F., Pecoraro, C., Visciano, B., Canavese, C., Radin, E., Stratta, P., Nordio, M., Benetti, E., Parolin, M., Alberici, F., Manenti, L., Brugnano, R., Manenti, F., Capitanini, A., Emma, F., Massella, L., Rosa, M., Mazzon, M., Basso, E., Besso, L., Lavacca, A., Mella, A., Bertero, M., Coppo, R., Peruzzi, L., Porcellini, M. G., Piccoli, G. B., Clari, R., Pasi, A., Gangemi, C., Alfandary, H., Dagan, A., Conceiçao, M., Sameiro, F. M., Croze, L., Malvezzi, P., Tsygin, A., Zelan, B., Nastasi, null, Iatropoulos, P, Daina, E, Curreri, M, Piras, R, Valoti, E, Mele, C, Bresin, E, Gamba, S, Alberti, M, Breno, M, Perna, A, Bettoni, S, Sabadini, E, Murer, L, Vivarelli, M, Noris, M, Remuzzi, G, Bottanelli, L, Donadelli, R, Cuccarolo, P, Abbate, M, Carrara, C, Cannata, A, Ferrari, S, Gaspari, F, Stucchi, N, Bassani, C, Lena, M, Omati, G, Taruscia, D, Bellantuono, R, Giordano, M, Messina, G, Caruso, M, Gotti, E, Mescia, F, Perticucci, E, Schieppati, A, Verdoni, L, Berto, M, Baraldi, O, Montini, G, Pasini, A, Passler, W, Degasperi, T, Gaggiotti, M, Gregorini, G, Miglietti, N, Guarnieri, A, Cirami, L, Roperto, R, Di Giorgio, G, Barbano, G, Innocenti, M, Ghiggeri, G, Magnasco, A, Rolla, D, Casartelli, D, Lambertini, D, Maggio, M, Cosci, P, Conti, G, Amar, K, Ardissino, G, Marinosci, A, Sinico, R, Montoli, A, Bonucchi, D, Facchini, F, Furci, L, Ferretti, A, Nuzzi, F, Pecoraro, C, Visciano, B, Canavese, C, Radin, E, Stratta, P, Nordio, M, Benetti, E, Parolin, M, Alberici, F, Manenti, L, Brugnano, R, Manenti, F, Capitanini, A, Emma, F, Massella, L, Rosa, M, Mazzon, M, Basso, E, Besso, L, Lavacca, A, Mella, A, Bertero, M, Coppo, R, Peruzzi, L, Porcellini, M, Piccoli, G, Clari, R, Pasi, A, Gangemi, C, Alfandary, H, Dagan, A, Conceiçao, M, Sameiro, F, Croze, L, Malvezzi, P, Tsygin, A, Zelan, B, and Nastasi, N
- Subjects
0301 basic medicine ,Complement system ,Glomerulonephritis, Membranoproliferative ,membranoproliferative glomerulonephritis (MPGN) ,030232 urology & nephrology ,Disease ,Antigen-Antibody Complex ,Biology ,Kidney ,03 medical and health sciences ,0302 clinical medicine ,Glomerulopathy ,Clinical Research ,medicine ,Dense Deposit Disease ,Humans ,C3 glomerulopathy ,General Medicine ,Complement System Proteins ,C3 glomerulonephriti ,medicine.disease ,C3-convertase ,Immune complex ,030104 developmental biology ,Nephrology ,Immunology ,Alternative complement pathway ,Nephrotic syndrome ,Rare disease - Abstract
Membranoproliferative GN (MPGN) was recently reclassified as alternative pathway complement–mediated C3 glomerulopathy (C3G) and immune complex–mediated membranoproliferative GN (IC-MPGN). However, genetic and acquired alternative pathway abnormalities are also observed in IC-MPGN. Here, we explored the presence of distinct disease entities characterized by specific pathophysiologic mechanisms. We performed unsupervised hierarchical clustering, a data-driven statistical approach, on histologic, genetic, and clinical data and data regarding serum/plasma complement parameters from 173 patients with C3G/IC-MPGN. This approach divided patients into four clusters, indicating the existence of four different pathogenetic patterns. Specifically, this analysis separated patients with fluid-phase complement activation (clusters 1–3) who had low serum C3 levels and a high prevalence of genetic and acquired alternative pathway abnormalities from patients with solid-phase complement activation (cluster 4) who had normal or mildly altered serum C3, late disease onset, and poor renal survival. In patients with fluid-phase complement activation, those in clusters 1 and 2 had massive activation of the alternative pathway, including activation of the terminal pathway, and the highest prevalence of subendothelial deposits, but those in cluster 2 had additional activation of the classic pathway and the highest prevalence of nephrotic syndrome at disease onset. Patients in cluster 3 had prevalent activation of C3 convertase and highly electron-dense intramembranous deposits. In addition, we provide a simple algorithm to assign patients with C3G/IC-MPGN to specific clusters. These distinct clusters may facilitate clarification of disease etiology, improve risk assessment for ESRD, and pave the way for personalized treatment.
- Published
- 2017
9. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases
- Author
-
Radice, A, Pieruzzi, F, Trezzi, B, Ghiggeri, G, Napodano, P, D’Amico, M, Stellato, T, Brugnano, R, Ravera, F, Rolla, D, Pesce, G, Giovenzana, M, Londrino, F, Cantaluppi, V, Pregnolato, F, Volpi, A, Rombolà, G, Moroni, G, Ortisi, G, Sinico, R, PIERUZZI, FEDERICO UMBERTO EMILIO GUGLIE, STELLATO, TIZIANA, MORONI, GABRIELLA, SINICO, RENATO ALBERTO, Radice, A, Pieruzzi, F, Trezzi, B, Ghiggeri, G, Napodano, P, D’Amico, M, Stellato, T, Brugnano, R, Ravera, F, Rolla, D, Pesce, G, Giovenzana, M, Londrino, F, Cantaluppi, V, Pregnolato, F, Volpi, A, Rombolà, G, Moroni, G, Ortisi, G, Sinico, R, PIERUZZI, FEDERICO UMBERTO EMILIO GUGLIE, STELLATO, TIZIANA, MORONI, GABRIELLA, and SINICO, RENATO ALBERTO
- Abstract
Autoantibody against phospholipase A2 receptor (anti-PLA2R) is a sensitive and specific biomarker of idiopathic membranous nephropathy (iMN), being found in approximately 70% of iMN patients and only occasionally in other glomerular diseases. However, whereas its diagnostic specificity vs. normal controls and other glomerulonephritides (GN) has been firmly established, its specificity vs. membranous nephropathy associated with various diseases (sMN) has given inconsistent results. The aim of our study was to evaluate the prevalence of anti-PLA2R antibodies in iMN in comparison with various control groups, including sMN. A total of 252 consecutive iMN patients, 184 pathological and 43 healthy controls were tested for anti-PLA2R antibody using indirect immunofluorescence (PLA2R IIFT, Euroimmun). Anti-PLA2R autoantibodies were detectable in 178/252 iMN patients, 1/80 primary GN, 0/72 secondary GN, 9/32 sMN and 0/43 healthy controls, with a diagnostic sensitivity of 70.6%. The diagnostic specificity of anti-PLA2R antibody vs. normal and pathological controls was 100 and 94.6% respectively. However, when the diagnostic specificity was calculated only vs. secondary forms of MN, it decreased considerably to 71.9%. Interestingly enough, 9 out of 10 anti-PLA2R positive patients in the disease control groups had membranous nephropathy associated with various diseases (7 cancer, 1 Crohn’s disease, 1 scleroderma). In conclusion, anti-PLA2R positivity in a patient with MN, should not be considered sufficient to abstain from seeking a secondary cause, especially in patients with risk factors for neoplasia. The causal relationship between tumors and anti-PLA2R-induced MN remains to be established, as well as the possible mechanisms through which malignancies provoke autoimmunity.
- Published
- 2018
10. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases
- Author
-
Radice, A., primary, Pieruzzi, F., additional, Trezzi, B., additional, Ghiggeri, G., additional, Napodano, P., additional, D’Amico, M., additional, Stellato, T., additional, Brugnano, R., additional, Ravera, F., additional, Rolla, D., additional, Pesce, G., additional, Giovenzana, M. E., additional, Londrino, F., additional, Cantaluppi, V., additional, Pregnolato, F., additional, Volpi, A., additional, Rombolà, G., additional, Moroni, G., additional, Ortisi, G., additional, and Sinico, Renato A., additional
- Published
- 2017
- Full Text
- View/download PDF
11. HCV infection: six years after'in a Dialysis unit
- Author
-
Francisci, Daniela, Buoncristiani, U., Brugnano, R., Gaburri, M., and Quintaliani, G.
- Subjects
hemodialysis ,HCV infection - Published
- 1999
12. Genetic diseases / Molecular mechanisms
- Author
-
Wanner, C., primary, Germain, D. P., additional, Linthorst, G., additional, Marodi, L., additional, Mauer, M., additional, Mignani, R., additional, Oliveira, J., additional, Ortiz, A., additional, Serra, A. L., additional, Svarstad, E., additional, Vujkovac, B., additional, Waldek, S., additional, Warnock, D. G., additional, West, M., additional, Schiffmann, R., additional, Mehta, A., additional, Amato, D., additional, Nair, N., additional, Zahrieh, D., additional, Huertas, P., additional, Bonatti, F., additional, Maritati, F., additional, Alberici, F., additional, Oliva, E., additional, Sinico, R. A., additional, Moroni, G., additional, Leoni, A., additional, Gregorini, G., additional, Jeannin, G., additional, Possenti, S., additional, Tumiati, B., additional, Grasselli, C., additional, Brugnano, R., additional, Salvarani, C., additional, Fraticelli, P., additional, Pavone, L., additional, Pesci, A., additional, Guida, G., additional, Neri, T. M., additional, Buzio, C., additional, Malerba, G., additional, Martorana, D., additional, Vaglio, A., additional, Oda, A., additional, Kitamura, K., additional, Mizumoto, T., additional, Eguchi, K., additional, Anzai, N., additional, Tomita, K., additional, Arsali, M., additional, Athanasiou, Y., additional, Demosthenous, P., additional, Voskarides, K., additional, Deltas, C., additional, and Pierides, A., additional
- Published
- 2011
- Full Text
- View/download PDF
13. Genetic diseases and molecular genetics
- Author
-
Stekrova, J., primary, Reiterova, J., additional, Elisakova, V., additional, Merta, M., additional, Kohoutova, M., additional, Tesar, V., additional, Suvakov, S., additional, Damjanovic, T., additional, Dimkovic, N., additional, Pljesa, S., additional, Savic-Radojevic, A., additional, Pljesa-Ercegovac, M., additional, Matic, M., additional, Djukic, T., additional, Coric, V., additional, Simic, T., additional, Gigante, M., additional, d'Altilia, M., additional, Montemurno, E., additional, Schirinzi, A., additional, Bruno, F., additional, Netti, G. S., additional, Ranieri, E., additional, Stallone, G., additional, Infante, B., additional, Grandaliano, G., additional, Gesualdo, L., additional, Maritati, F., additional, Alberici, F., additional, Bonatti, F., additional, Oliva, E., additional, Sinico, R. A., additional, Moroni, G., additional, Leoni, A., additional, Gregorini, G., additional, Jeannin, G., additional, Possenti, S., additional, Tumiati, B., additional, Grasselli, C., additional, Brugnano, R., additional, Salvarani, C., additional, Fraticelli, P., additional, Pavone, L., additional, Pesci, A., additional, Guida, G., additional, Neri, T. M., additional, Buzio, C., additional, Malerba, G., additional, Martorana, D., additional, Vaglio, A., additional, Santucci, L., additional, Candiano, G., additional, Cremasco, D., additional, Tosetto, E., additional, Del Prete, D., additional, Bruschi, M., additional, Ghiggeri, G. M., additional, Anglani, F., additional, Rainone, F., additional, Soldati, L., additional, Terranegra, A., additional, Arcidiacono, T., additional, Aloia, A., additional, Dogliotti, E., additional, Vezzoli, G., additional, Maruniak-Chudek, I., additional, Zenker, M., additional, Chudek, J., additional, Obeidova, L., additional, Stekrova, J., additional, Lnenicka, P., additional, Iwanitskiy, L. V., additional, Krasnova, T. N., additional, Samokhodskaya, L. M., additional, Bernasconi, A. R., additional, Albarracin, L., additional, Liste, A. A., additional, Politei, J. M., additional, Heguilen, R. M., additional, Kaito, H., additional, Nozu, K., additional, Nakanishi, K., additional, Hashimura, Y., additional, Shima, Y., additional, Ninchoji, T., additional, Yoshikawa, N., additional, Iijima, K., additional, Matsuo, M., additional, Hur, E., additional, Gungor, O., additional, Bozkurt, D., additional, Bozgul, S. M. K., additional, Caliskan, H., additional, Dusunur, F., additional, Basci, A., additional, Akcicek, F., additional, Duman, S., additional, Li, Y., additional, Wang, C., additional, Nan, L., additional, Hruskova, Z., additional, Brabcova, I., additional, Lanska, V., additional, Honsova, E., additional, Hanzal, V., additional, Borovicka, V., additional, Rysava, R., additional, Zachoval, R., additional, Viklicky, O., additional, Miltenberger-Miltenyi, G., additional, Almeida, E., additional, Calado, J., additional, Carvalho, F., additional, Pereira, S., additional, Teixeira, C., additional, Jorge, S., additional, Viana, H., additional, Gomes da Costa, A., additional, Yang, C.-S., additional, Tseng, M.-H., additional, Yang, S.-S., additional, and Lin, S.-H., additional
- Published
- 2011
- Full Text
- View/download PDF
14. DAILY RECYCLED BICARBONATE DIALYSIS WITH POLYACRYLONITRILE
- Author
-
Buoncristiani, U., Giombini, L., Cozzari, M., Carobi, C., Quintaliani, G., and Brugnano, R.
- Published
- 1983
15. Acute renal and hepatic failure associated with allopurinol treatment
- Author
-
Fagugli, R.M., primary, Gentile, G., additional, Ferrara, G., additional, and Brugnano, R., additional
- Published
- 2008
- Full Text
- View/download PDF
16. Viral Infections in the Kidney Transplant
- Author
-
Quintaliani, G., Brugnano, R., Francisci, D., Buoncristiani, U., Quintaliani, G., Brugnano, R., Francisci, D., and Buoncristiani, U.
- Abstract
No abstract, non disponibile
- Published
- 1994
17. Nutrition in Renal Transplantation
- Author
-
Quintaliani, G., Demegni, L., Brugnano, R., Pittavini, L., Buoncristiani, U., Quintaliani, G., Demegni, L., Brugnano, R., Pittavini, L., and Buoncristiani, U.
- Abstract
No abstract, non disponibile
- Published
- 1993
18. Infezioni Virali Nel Trapiantato Renale
- Author
-
Quintaliani, G., primary, Brugnano, R., additional, Francisci, D., additional, and Buoncristiani, U., additional
- Published
- 1994
- Full Text
- View/download PDF
19. La Nutrizione Nel Trapianto Renale
- Author
-
Quintaliani, G., primary, Demegni, L., additional, Brugnano, R., additional, Pittavini, L., additional, and Buoncristiani, U., additional
- Published
- 1993
- Full Text
- View/download PDF
20. Antibodies against Hepatitis C Virus in Hemodialysis Patients in the Central Italian Region of Umbria: Evaluation of Some Risk Factors
- Author
-
Brugnano, R., primary, Francisci, D., additional, Quintaliani, G., additional, Gaburri, M., additional, Nori, G., additional, Verdura, C., additional, Giombini, L., additional, and Buoncristiani, U., additional
- Published
- 1992
- Full Text
- View/download PDF
21. Infezioni Virali Nel Trapiantato Renale
- Author
-
Quintaliani, G., Brugnano, R., Francisci, D., and Buoncristiani, U.
- Published
- 1994
- Full Text
- View/download PDF
22. Cytomegalovirus colitis in a patient with recent failure of kidney transplant.
- Author
-
Gaburri, M., Brugnano, R., Cozzari, M., Francisci, D., Stagni, G., and Buoncristiani, U.
- Published
- 1993
23. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases
- Author
-
M E Giovenzana, Gian Marco Ghiggeri, G Ortisi, Federico Pieruzzi, F Ravera, Antonella Radice, Marco D'Amico, Renato Alberto Sinico, Francesco Londrino, V Cantaluppi, Pietro Napodano, Giampaola Pesce, T Stellato, Gabriella Moroni, D Rolla, R Brugnano, Francesca Pregnolato, A Volpi, Barbara Trezzi, G Rombolà, Radice, A, Pieruzzi, F, Trezzi, B, Ghiggeri, G, Napodano, P, D’Amico, M, Stellato, T, Brugnano, R, Ravera, F, Rolla, D, Pesce, G, Giovenzana, M, Londrino, F, Cantaluppi, V, Pregnolato, F, Volpi, A, Rombolà, G, Moroni, G, Ortisi, G, and Sinico, R
- Subjects
Nephrology ,Male ,medicine.medical_specialty ,Glomerulonephritis, Membranoproliferative ,030232 urology & nephrology ,Disease ,030204 cardiovascular system & hematology ,medicine.disease_cause ,Gastroenterology ,Glomerulonephritis, Membranous ,Sensitivity and Specificity ,Autoimmunity ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Glomerulonephritis ,Membranous nephropathy ,Crohn Disease ,Autoantibody to phospholipase A2 receptor, Idiopathic membranous nephropathy, Secondary membranous nephropathy, diagnostic specificity ,Internal medicine ,Neoplasms ,medicine ,Secondary membranous nephropathy, diagnostic specificity ,Humans ,Aged ,Autoantibodies ,Retrospective Studies ,Idiopathic membranous nephropathy ,biology ,business.industry ,Glomerulosclerosis, Focal Segmental ,Receptors, Phospholipase A2 ,Autoantibody ,Cancer ,Glomerulonephritis, IGA ,Middle Aged ,medicine.disease ,Lupus Nephritis ,Secondary membranous nephropathy ,Autoantibody to phospholipase A2 receptor ,Immunology ,biology.protein ,diagnostic specificity ,Biomarker (medicine) ,Female ,Antibody ,business - Abstract
Autoantibody against phospholipase A2 receptor (anti-PLA2R) is a sensitive and specific biomarker of idiopathic membranous nephropathy (iMN), being found in approximately 70% of iMN patients and only occasionally in other glomerular diseases. However, whereas its diagnostic specificity vs. normal controls and other glomerulonephritides (GN) has been firmly established, its specificity vs. membranous nephropathy associated with various diseases (sMN) has given inconsistent results. The aim of our study was to evaluate the prevalence of anti-PLA2R antibodies in iMN in comparison with various control groups, including sMN. A total of 252 consecutive iMN patients, 184 pathological and 43 healthy controls were tested for anti-PLA2R antibody using indirect immunofluorescence (PLA2R IIFT, Euroimmun). Anti-PLA2R autoantibodies were detectable in 178/252 iMN patients, 1/80 primary GN, 0/72 secondary GN, 9/32 sMN and 0/43 healthy controls, with a diagnostic sensitivity of 70.6%. The diagnostic specificity of anti-PLA2R antibody vs. normal and pathological controls was 100 and 94.6% respectively. However, when the diagnostic specificity was calculated only vs. secondary forms of MN, it decreased considerably to 71.9%. Interestingly enough, 9 out of 10 anti-PLA2R positive patients in the disease control groups had membranous nephropathy associated with various diseases (7 cancer, 1 Crohn's disease, 1 scleroderma). In conclusion, anti-PLA2R positivity in a patient with MN, should not be considered sufficient to abstain from seeking a secondary cause, especially in patients with risk factors for neoplasia. The causal relationship between tumors and anti-PLA2R-induced MN remains to be established, as well as the possible mechanisms through which malignancies provoke autoimmunity.
- Published
- 2018
24. Physical activity and exercise in chronic kidney disease: consensus statements from the Physical Exercise Working Group of the Italian Society of Nephrology.
- Author
-
Battaglia Y, Baciga F, Bulighin F, Amicone M, Mosconi G, Storari A, Brugnano R, Pozzato M, Motta D, D'alessandro C, Torino C, Mallamaci F, Cupisti A, Aucella F, and Capitanini A
- Subjects
- Humans, Quality of Life, Italy, Renal Insufficiency, Chronic therapy, Renal Insufficiency, Chronic physiopathology, Exercise, Consensus, Exercise Therapy methods, Nephrology standards
- Abstract
The Italian Society of Nephrology has tasked its Working Group on Physical Exercise with developing a consensus statement document on physical activity and exercise in patients with chronic kidney disease (CKD). This paper consists of 16 points that were discussed, and approved using the mini-Delphi method by 15 members of the working group. Each statement is based on a comprehensive review of the literature, clinical experience, and expert opinions. Overall, the statements affirm that regular physical activity and exercise training offer numerous benefits to CKD patients, including improved physical function, enhanced cardiometabolic and neuromuscular function, cognitive benefits, and an overall improvement in quality of life. Furthermore, exercise may provide nephroprotection and reduce mortality. These advantages are observed across all CKD stages, whether on conservative therapy or kidney replacement therapy (hemodialysis or peritoneal dialysis), and in kidney transplant recipients. Moreover, when physical activity and exercise training are implemented with appropriate precautions, they are safe in CKD patients. Gradual physical activity and customized exercise programs should be tailored to the patient's exercise tolerance, potentially enhancing compliance. Clinicians are encouraged to use a series of questionnaires and tests to assess the patient's level of physical activity and performance. However, exercise and physical activity are poorly implemented in clinical practice due to many barriers related to patients and healthcare staff. Overcoming these barriers requires the proactive role of the nephrologists, who should actively incorporate exercise training and promote physical activity within routine care plans. Adopting a multidisciplinary team approach, which includes nephrologists, nurses, exercise professionals, and dietitians, is crucial for providing comprehensive rehabilitation for CKD patients. Integrating new technologies and remote check ups could further enhance the effectiveness of these interventions., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
25. The risks associated with percutaneous native kidney biopsies: a prospective study.
- Author
-
Andrulli S, Rossini M, Gigliotti G, La Manna G, Feriozzi S, Aucella F, Granata A, Moggia E, Santoro D, Manenti L, Infante B, Ferrantelli A, Cianci R, Giordano M, Giannese D, Seminara G, Di Luca M, Bonomini M, Spatola L, Bruno F, Baraldi O, Micarelli D, Piemontese M, Distefano G, Mattozzi F, De Giovanni P, Penna D, Garozzo M, Vernaglione L, Abaterusso C, Zanchelli F, Brugnano R, Gintoli E, Sottini L, Quaglia M, Cavoli GL, De Fabritiis M, Conte MM, Manes M, Battaglia Y, Fontana F, and Gesualdo L
- Subjects
- Humans, Middle Aged, Prospective Studies, Retrospective Studies, Creatinine, Biopsy, Kidney pathology
- Abstract
Background: The known risks and benefits of native kidney biopsies are mainly based on the findings of retrospective studies. The aim of this multicentre prospective study was to evaluate the safety of percutaneous renal biopsies and quantify biopsy-related complication rates in Italy., Methods: The study examined the results of native kidney biopsies performed in 54 Italian nephrology centres between 2012 and 2020. The primary outcome was the rate of major complications 1 day after the procedure, or for longer if it was necessary to evaluate the evolution of a complication. Centre and patient risk predictors were analysed using multivariate logistic regression., Results: Analysis of 5304 biopsies of patients with a median age of 53.2 years revealed 400 major complication events in 273 patients (5.1%): the most frequent was a ≥2 g/dL decrease in haemoglobin levels (2.2%), followed by macrohaematuria (1.2%), blood transfusion (1.1%), gross haematoma (0.9%), artero-venous fistula (0.7%), invasive intervention (0.5%), pain (0.5%), symptomatic hypotension (0.3%), a rapid increase in serum creatinine levels (0.1%) and death (0.02%). The risk factors for major complications were higher plasma creatinine levels [odds ratio (OR) 1.12 for each mg/dL increase, 95% confidence interval (95% CI) 1.08-1.17], liver disease (OR 2.27, 95% CI 1.21-4.25) and a higher number of needle passes (OR for each pass 1.22, 95% CI 1.07-1.39), whereas higher proteinuria levels (OR for each g/day increase 0.95, 95% CI 0.92-0.99) were protective., Conclusions: This is the first multicentre prospective study showing that percutaneous native kidney biopsies are associated with a 5% risk of a major post-biopsy complication. Predictors of increased risk include higher plasma creatinine levels, liver disease and a higher number of needle passes., (© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2023
- Full Text
- View/download PDF
26. Case Report: Optic Atrophy and Nephropathy With m.13513G>A/MT-ND5 mtDNA Pathogenic Variant.
- Author
-
Barone V, La Morgia C, Caporali L, Fiorini C, Carbonelli M, Gramegna LL, Bartiromo F, Tonon C, Morandi L, Liguori R, Petrini A, Brugnano R, Del Sordo R, Covarelli C, Morroni M, Lodi R, and Carelli V
- Abstract
Isolated complex I deficiency represents the most common mitochondrial respiratory chain defect involved in mitochondrial disorders. Among these, the mitochondrial DNA (mtDNA) m.13513G>A pathogenic variant in the NADH dehydrogenase 5 subunit gene (MT-ND5) has been associated with heterogenous manifestations, including phenotypic overlaps of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes, Leigh syndrome, and Leber's hereditary optic neuropathy (LHON). Interestingly, this specific mutation has been recently described in patients with adult-onset nephropathy. We, here, report the unique combination of LHON, nephropathy, sensorineural deafness, and subcortical and cerebellar atrophy in association with the m.13513G>A variant., Competing Interests: VC acts as a consultant on boards for GenSight Biologics, Chiesi Farmaceutici, Stealth Biotherapeutics, and Pretzel Therapeutics and is PI in sponsored clinical trials by Santhera Pharmaceuticals, GenSight Biologics, Stealth Biotherapeutics. CL: consultancies for Chiesi Farmaceutici, Regulatory Pharma Net, and Thenewway srl; speaker honoraria from Santhera Pharmaceuticals, Chiesi Farmaceutici, Regulatory Pharma Net, Thenewway srl, First Class srl, and Biologix; PI/SI for clinical trials sponsored GenSight Biologics and Santhera Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Barone, La Morgia, Caporali, Fiorini, Carbonelli, Gramegna, Bartiromo, Tonon, Morandi, Liguori, Petrini, Brugnano, Del Sordo, Covarelli, Morroni, Lodi and Carelli.)
- Published
- 2022
- Full Text
- View/download PDF
27. PLA2R Immunohistochemistry Staining in Membranous Glomerulopathy: A Challenging Stain to Interpret But a Potentially Useful Diagnostic Tool.
- Author
-
Del Sordo R, Covarelli C, Brugnano R, Sciri R, Bellezza G, Mandarano M, and Sidoni A
- Subjects
- Adult, Aged, Aged, 80 and over, Biopsy, Disease Progression, Female, Humans, Immunohistochemistry, Kidney pathology, Male, Middle Aged, Prognosis, Glomerulonephritis, Membranous diagnosis, Kidney metabolism, Receptors, Phospholipase A2 metabolism, Staining and Labeling methods
- Abstract
Circulating autoantibodies to phospholipase A2 receptor (PLA2R-Ab) are detected in >70% of patients with primary membranous glomerulonephritis (MGN). Detection of PLA2R antigen in renal tissue, with immunohistochemistry (PLA2R IHC), strongly correlates with serum PLA2R-Ab, although it is more sensitive. As PLA2R IHC in literature has no univocal interpretation, we suggest reliable criteria for a standard approach for the assessment of immunostaining for differential diagnosis between primary and secondary MGN. We analyzed PLA2R IHC expression in 40 biopsies of patients with MGN and serum PLA2R-Ab titer at the time of biopsy. We carefully evaluated, at high magnification, the immunostaining pattern and distribution, regardless of intensity, in capillary loops, mesangium, and podocytes of all glomeruli.We defined, adopting this approach, positive stain when a granular pattern, coarse and/or fine, diffuse or focal, and global or segmental were observed. Negative stain was defined by mesangial staining, when there was a dirty pattern, or a peripheral staining of capillary loops with a smoky linear pattern. Podocytes showed homogenous cytoplasmatic stain both in positive and negative cases and in external negative controls. We found PLA2R IHC and serum PLA2R-Ab positivity in early-middle stage MGN compared with advanced stage more frequently. Correct stratification of patients with MGN needs PLA2R-Ab detection in serum and renal tissue. PLA2R IHC test, although a challenging stain, can be an easy diagnostic tool but requires reliable interpretation keys for a standard approach to the assessment of immunostaining., Competing Interests: The authors declare no conflict of interest., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
28. [Relevance of an accurate microscopic examination of urinary sediment in a patient after mitral valve surgery].
- Author
-
Covarelli C, Brugnano R, Pasquino S, Buoncristiani E, Del Sordo R, and Sidoni A
- Subjects
- Echocardiography, Transesophageal, Humans, Mitral Valve diagnostic imaging, Mitral Valve surgery, Anemia, Hemolytic diagnosis, Anemia, Hemolytic etiology, Cardiac Surgical Procedures, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency etiology, Mitral Valve Insufficiency surgery
- Abstract
Hemoglobinuria, clinically revealing as gross hematuria associated with anemia, increased hemolysis indices, acute kidney injury (AKI), can all be caused by mechanical intravascular hemolysis following mitral valve surgery. It can result from factors related to the surgical procedure or acquired later, such as paravalvular leak (PL), whose definite diagnosis is based on transesophageal echocardiography. We report the case of a patient who experienced macrohematuria and AKI, initially attributed to acute glomerulonephritis, two months after mitral valve surgery. Careful microscopic examination of the urinary sediment was a diriment diagnostic tool to differentiate acute renal failure caused by hemoglobinuria from hematuria in the course of acute glomerulonephritis, directing clinicians to investigate post-operative valvular dysfunction. From the literature review we can deduce that, notwithstanding new technologies in cardiac surgery, this rare form of AKI from intravascular hemolysis requires immediate nephrological attention and that the use of microscopic urinary sediment is decisive., (Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.)
- Published
- 2021
29. Renal involvement in sarcoidosis: histological patterns and prognosis, an Italian survey.
- Author
-
Rastelli F, Baragetti I, Buzzi L, Ferrario F, Benozzi L, Di Nardo F, Devoti E, Cancarini G, Mezzina N, Napodano P, Gallieni M, Santoro D, Buemi M, Pecchini P, Malberti F, Colombo V, Colussi G, Sabadini E, Remuzzi G, Argentiero L, Gesualdo L, Gatti G, Trevisani F, Slaviero G, Spotti D, Baraldi O, La Manna G, Pignone E, Saltarelli M, Heidempergher M, Tedesco M, Genderini A, Ferro M, Rollino C, Roccatello D, Guzzo G, Clari R, Barbara Piccoli G, Comotti C, Brunori G, Cameli P, Bargagli E, Rottoli P, Dugo M, Cristina Maresca M, Bertoli M, Giozzet M, Brugnano R, Giovanni Nunzi E, D'Amico M, Minoretti C, Acquistapace I, Colturi C, Minola E, Camozzi M, Tosoni A, Nebuloni M, Ferrario F, Dell'Antonio G, Cusinato S, Feriozzi S, and Pozzi C
- Abstract
Background: Granulomatous interstitial nephritis in sarcoidosis (sGIN) is generally clinically silent, but in <1% causes acute kidney injury (AKI)., Methods: This Italian multicentric retrospective study included 39 sarcoidosis-patients with renal involvement at renal biopsy: 31 sGIN-AKI, 5 with other patterns (No-sGIN-AKI), 3 with nephrotic proteinuria. We investigate the predictive value of clinical features, laboratory, radiological parameters and histological patterns regarding steroid response. Primary endpoint: incident chronic kidney disease (CKD) beyond the 1°follow-up (FU) year; secondary endpoint: response at 1°line steroid therapy; combined endpoint: the association of initial steroid response and outcome at the end of FU., Results: Complete recovery in all 5 No-sGIN-AKI-patients, only in 45% (13/29) sGIN-AKI-patients (p=0.046) (one lost in follow-up, for another not available renal function after steroids). Nobody had not response. Primary endpoint of 22 sGIN-AKI subjects: 65% (13/20) starting with normal renal function developed CKD (2/22 had basal CKD; median FU 77 months, 15-300). Combined endpoint: 29% (6/21) had complete recovery and final normal renal function (one with renal relapse), 48% (10/21) had partial recovery and final CKD (3 with renal relapse, of whom one with basal CKD) (p=0.024). Acute onset and hypercalcaemia were associated to milder AKI and better recovery than subacute onset and patients without hypercalcaemia, women had better endpoints than men. Giant cells, severe interstitial infiltrate and interstitial fibrosis seemed negative predictors in terms of endpoints., Conclusions: sGIN-AKI-patients with no complete recovery at 1°line steroid should be treated with other immunosuppressive to avoid CKD, in particular if males with subacute onset and III stage-not hypercalcaemic AKI., Competing Interests: Special thanks to Jacqueline Rodriguez, who revised the manuscript for English language, and to Claudia Giuliani, for graphic support. We express gratitude to Immunopathology Group of Italian Society of Nephrology and to ACSI Onlus “Amici contro la Sarcoidosi Italia”, the Italian national society of Sarcoidosis patients.Francesco Rastelli and Ivano Baragetti were responsible for the work. Other authors contributed to the data collection and reviewed and revised the manuscript as supervisors.Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article., (Copyright: © 2021 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES.)
- Published
- 2021
- Full Text
- View/download PDF
30. Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.
- Author
-
Del Sordo R, Brugnano R, Covarelli C, Fiorucci G, Falzetti F, Barbatelli G, Nunzi E, and Sidoni A
- Abstract
Primary myelofibrosis (PMF) is an uncommon form of myeloproliferative neoplasm (MPN) characterized by a proliferation of predominantly megakaryocytes and granulocytes in the bone marrow that, in fully-developed disease, is associated with reactive deposition of fibrous connective tissue, extramedullary hematopoiesis (EMH), and splenomegaly. Kidney involvement is rare and clinically presents with proteinuria, nephrotic syndrome, and renal insufficiency. Renal damage can be due to EMH and glomerulopathy. Renal EMH presents three patterns: infiltration of the interstitium with possible renal failure caused by functional damage of parenchyma and vessels, infiltration of capsule and pericapsular adipose tissue, and sclerosing mass-like lesions that can cause hydronephrosis and hydroureter with obstructive uropathy and renal failure. Glomerulopathy associated with PMF is rarely described, ranging from 1 month to 18 years from diagnosis of the neoplasm to renal biopsy. It is characterized by expansion and hypercellularity mesangial, segmental sclerosis, features of chronic thrombotic microangiopathy (TMA), and intracapillary hematopoietic cells infiltrating in absence of immune-mediated glomerulonephritis. We present a nephrotic syndrome in PMF-related glomerulopathy, associated with EMH, without renal failure, in a patient under treatment for 2 years with JAK2 inhibitor ruxolitinib. Despite treatment, the patient died 7 months after renal biopsy. Nephrologists still know very little about this topic and there is no homogeneous data about incidence, pathogenesis, and optimal treatment of this poor prognostic PMF-associated nephrotic syndrome. We focus on data in the literature in the hope of stimulating hematologists, nephrologists, pathologists to future studies about the natural history of renal involvement, useful for optimal management of this rare pathology.
- Published
- 2017
- Full Text
- View/download PDF
31. WITHDRAWN: Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.
- Author
-
Sordo RD, Brugnano R, Covarelli C, Fiorucci G, Falzetti F, Barbatelli G, Nunzi E, and Sidoni A
- Abstract
Ahead of Print article withdrawn by publisher. The publisher apologizes for any inconvenience this has caused. The article was scheduled for the journal "Clinical Nephrology. Case Studies" (issn 2196-5293). The article is available in PubmedCentral: https://www.ncbi.nlm.nih.gov/pubmed/29350220 .
- Published
- 2017
- Full Text
- View/download PDF
32. PTPN22 R620W polymorphism in the ANCA-associated vasculitides.
- Author
-
Martorana D, Maritati F, Malerba G, Bonatti F, Alberici F, Oliva E, Sebastio P, Manenti L, Brugnano R, Catanoso MG, Fraticelli P, Guida G, Gregorini G, Possenti S, Moroni G, Leoni A, Pavone L, Pesci A, Sinico RA, Di Toma L, D'Amico M, Tumiati B, D'Ippolito R, Buzio C, Neri TM, and Vaglio A
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Alleles, Female, Gene Frequency, Genetic Association Studies, Genotype, Humans, Male, Middle Aged, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis genetics, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Protein Tyrosine Phosphatase, Non-Receptor Type 22 genetics
- Abstract
Objectives: PTPN22 is involved in T-cell activation and its R620W single-nucleotide polymorphism (SNP) has been shown to predispose to different autoimmune diseases. The aims of this study were to investigate the role of the PTPN22 R620W SNP in conferring susceptibility to the ANCA-associated vasculitides (AAVs), and to explore potential associations between the PTPN22 genotype and the disease manifestations., Methods: PTPN22 R620W SNP was genotyped in a cohort of 344 AAV patients [143 with granulomatosis with polyangiitis (Wegener's) (GPA), 102 with microscopic polyangiitis (MPA) and 99 with Churg-Strauss syndrome (CSS)] and in 945 healthy controls., Results: The frequency of the minor allele (620W) was significantly higher in GPA patients than in controls [P = 0.005, χ(2 )= 7.858, odds ratio (OR) = 1.91], while no statistically significant association was found with MPA or CSS. Among GPA patients, the 620W allele was particularly enriched in ANCA-positive patients as compared with controls (P = 0.00012, χ(2 )= 14.73, OR = 2.31); a particularly marked association was also found with ENT involvement (P = 0.0071, χ(2 )= 7.258, OR = 1.98), lung involvement (P = 0.0060, χ(2 )= 7.541, OR = 2.07) and skin manifestations of all kinds (P = 0.000047, χ(2 )= 16.567, OR = 3.73)., Conclusion: The PTPN22 620W allele confers susceptibility to the development of GPA (but not of MPA or CSS), and particularly of its ANCA-positive subset.
- Published
- 2012
- Full Text
- View/download PDF
33. IgA glomerulonephritis associated with Churg-Strauss syndrome.
- Author
-
De Stefano R, Frati E, Brugnano R, Covarelli C, Pittavini L, and Sidoni A
- Subjects
- Adrenal Cortex Hormones therapeutic use, Adult, Biopsy, Churg-Strauss Syndrome diagnosis, Churg-Strauss Syndrome drug therapy, Churg-Strauss Syndrome immunology, Female, Fluorescent Antibody Technique, Glomerulonephritis, IGA diagnosis, Glomerulonephritis, IGA drug therapy, Glomerulonephritis, IGA immunology, Humans, Immunosuppressive Agents therapeutic use, Middle Aged, Treatment Outcome, Churg-Strauss Syndrome complications, Glomerulonephritis, IGA etiology
- Published
- 2011
34. Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis.
- Author
-
Bergesio F, Ciciani AM, Santostefano M, Brugnano R, Manganaro M, Palladini G, Di Palma AM, Gallo M, Tosi PL, and Salvadori M
- Subjects
- Adult, Aged, Aged, 80 and over, Amyloidosis classification, Amyloidosis pathology, Cohort Studies, Female, Humans, Incidence, Italy epidemiology, Kidney Diseases pathology, Male, Middle Aged, Retrospective Studies, Amyloidosis diagnosis, Amyloidosis epidemiology, Kidney Diseases diagnosis, Kidney Diseases epidemiology
- Abstract
Background: Few data are available on epidemiology and clinical picture of renal involvement in different forms of systemic amyloidosis., Methods: Patients with biopsy-proven systemic amyloidosis diagnosed in Italy between January 1995 and December 2000 were selected from 49 Nephrology and Internal Medicine Units provided they showed signs characteristic of renal involvement. Clinical and laboratory information were collected by using a specific data form for diagnosis integrated by a questionnaire on diagnostic tools. Collected data were matched both with the Italian Registry of Renal Biopsies (IRRB) and the Registry of the Italian Society of Amyloidosis (SIA) in order to approximate the incidence of the disease., Results: Of all patients, 373 were finally selected throughout Italy with an estimated mean incidence of renal amyloidosis of 2.1 per million population (p.m.p.) per year. Of those, 237 were affected from AL (primary) amyloidosis, 104 from AA (secondary) amyloidosis and 6 from AF (heredofamilial) forms. In 26 cases the type of amyloidosis remained undetermined. Among patients with AL, 36 presented an associated multiple myeloma (MM). Rheumatoid arthritis (RA) was the commonest underlying disease in AA. Median age ranged between 63 and 65 years in all groups. Males were prevalent in AL and females in AA. The main clinical features of renal involvement were represented by nephrotic syndrome and renal failure observed in 59 and 54% of cases, respectively. The presence of a lambda light chain, either in serum or urine was significantly associated to a more elevated urinary protein loss and to a reduced renal function. Patients with AA showed a worse renal function at presentation than patients with AL, possibly due to a late diagnosis and/or referral to nephrology units. Diagnosis was obtained by renal biopsy in 315 cases, by abdominal fat tissue (AFT) aspiration/biopsy in 156 patients and by other organ biopsies in 47 patients. Characterization of deposits was extremely variable among referring centres., Conclusions: Our results point to an increased incidence of renal amyloidosis observed in Italy over the period 1996-2000 with AL as the prevalent type. Characterization of amyloid deposits still remains the major diagnostic challenge of the disease. The institution of networks dedicated to rare diseases is strongly recommended in order to effectively afford this challenge.
- Published
- 2007
- Full Text
- View/download PDF
35. [Urinalysis in a nephrological laboratory: a precious art but too expensive?].
- Author
-
Covarelli C, Brugnano R, and Nasimi M
- Subjects
- Cost-Benefit Analysis, Cystoscopy economics, Diagnostic Imaging economics, Diagnostic Tests, Routine economics, Hematuria diagnosis, Hematuria economics, Hematuria urine, Humans, Italy, Laboratories, Hospital economics, Urine cytology, Urinalysis economics
- Published
- 2002
36. HCV Infection:'Six years after' in a dialysis unit.
- Author
-
Brugnano R, Gaburri M, Francisci D, Quintaliani G, and Buoncristiani U
- Subjects
- Humans, Program Evaluation, Facility Design and Construction, Hemodialysis Units, Hospital organization & administration, Hepatitis C, Infection Control organization & administration, Renal Dialysis
- Published
- 1999
- Full Text
- View/download PDF
37. [Continuous ambulatory peritoneal dialysis in patients with polycystic nephropathy].
- Author
-
Carobi C, Cozzari M, Brugnano R, Giombini L, and Buoncristiani U
- Subjects
- Bacterial Infections etiology, Catheters, Indwelling adverse effects, Female, Humans, Kidney Failure, Chronic etiology, Male, Middle Aged, Kidney Failure, Chronic therapy, Peritoneal Dialysis, Continuous Ambulatory, Polycystic Kidney Diseases complications
- Published
- 1985
38. [A new dialysis folder: 1987].
- Author
-
Ragaiolo M, Perucci V, Pala E, Bruni F, Damiani C, Brugnano R, Squarcia C, and Ciccanti R
- Subjects
- Humans, Medical Records, Renal Dialysis
- Published
- 1989
39. Biofiltration with buffer-free dialysate.
- Author
-
Buoncristiani U, Ragaiolo M, Petrucci V, Bruni F, Pala E, Damiani C, and Brugnano R
- Subjects
- Acetates administration & dosage, Adult, Bicarbonates administration & dosage, Buffers, Female, Hemodynamics, Humans, Male, Middle Aged, Osmolar Concentration, Rheology, Sodium, Ultrafiltration instrumentation, Blood, Renal Dialysis, Ultrafiltration methods
- Abstract
The presence of acetate in the dialysate appears to be superfluous in the new depurative technique indicated as biofiltration, which consists in a standard hemodialysis with high ultrafiltration combined with the reinfusion of 3-4 1/2 liters of solution containing bicarbonate. The presence of acetate could in fact be contraindicated by a number of potential side effects, metabolic, cardiovascular and biological. Hence, starting from the consideration that in standard biofiltration a buffer is already infused directly as bicarbonate, we tried to overcome the potential hazards of the acetate-containing bath simply by using a dialysate without acetate and by increasing the concentration of bicarbonate in the reinfusate. A cumulative clinical experience of 20 months in 4 patients proved the feasibility and safety of the technique and suggests further advantages over standard biofiltration (better control of acid-base equilibrium, better cardiovascular stability.
- Published
- 1986
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.